Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 16, 2022 4:30pm
122 Views
Post# 35176835

RE:The SMOKING Gun!!!

RE:The SMOKING Gun!!!Oh no... jd is concerned that BTI will be a 'therapeutics company' like multi-billion market cap Denali Therapeutics(NASDAQ: DNLI). BTI will no longer just license a component of drugs but be able to develop a pipeline of therapeutics all on its own internally just like Denali Therapeutics!



Denali Therapeutics Inc. DNLI

 

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

JDavenport wrote: It's my turn to do a little copy/pasting.

Here is Midatech stating its intentions in its filing concerning this deal.

The Board believes that the Acquisition is a compelling strategic opportunity to advance the Company's repurposed strategy and is expected to deliver a number of key benefits to Midatech and its shareholders, including:
  • transition from a drug delivery platform-based company to a therapeutics company;
You can read the passage starting << here >>.

Therapeutics! Right? Not "a drug delivery platform-based company..."

You see, the moment Midatech acquires Bioasis, it will own the xB3 platform and it will be "a drug delivery platform-based company." But then it will "transition from a drug delivery platform-based company to a therapeutics company;, 

So it's not going to be "a drug delivery platform-based company..."??

Is that the cover-yer-you-know-what statement, the smoking gun evidence and forewarning that xB3, a drug delivery platform, will not be a part of Biodexa's future?

There is no other resonable interpretation than that.

This tells you, outright, that, going forward, Biodexa will not have ownership of the xB3 platform and neither will you.

Gone.

No new big xB3 deals for Biodexa.

No xB3-001. (No surprise, xb3-001 is not metioned once anywhere in any deal announcement or document.)

It also means no new intellectual property at Biodexa without either hard basic R&D work or program acquisitions from outside. Biodexa will have to slug it out like every other two-bit biotech does.

They had to tell this, and there it is.

What they won't tell you because they can claim that they don't know, is who will help Biodexa achieve its goals by buying the xB3 platform and taking it off Biodexa's hands.

There it is, in all of its terrible glory.

Don't take my word for it. Take theirs.

jd


<< Previous
Bullboard Posts
Next >>